Tetra Radar · FDA Approvals · Decision date

obexelimab: FDA decision date

Zenas BioPharma, Inc. (ZBIO) · 27 May 2027

Food and Drug Administration (FDA) accepted the Company’s Biologics License Application (BLA) for obexelimab for the treatment of Immunoglobulin G4-Related Disease (IgG4-RD): The BLA, which was accepted in August, is under active review by the FDA and has been assigned a Prescription Drug User Fee Act (PDUFA) target action date of May 27, 2027.

Source: 8-K of 5 November 2026

The decision is pending.

A PDUFA date is the date by which the FDA has said it will decide on an application. Dates can move, and a decision is not an approval. Tetra Radar observes public information for research purposes. It does not provide investment advice.

Get the Dispatch free.